116 related articles for article (PubMed ID: 15370707)
1. Enzyme replacement therapy in severe Fabry disease with renal failure: a 1-year follow-up.
Tsambaos D; Chroni E; Manolis A; Monastirli A; Pasmatzi E; Sakkis T; Davlouros P; Goumenos D; Katrivanou A; Georgiou S
Acta Derm Venereol; 2004; 84(5):389-92. PubMed ID: 15370707
[TBL] [Abstract][Full Text] [Related]
2. Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy.
Mignani R; Feriozzi S; Schaefer RM; Breunig F; Oliveira JP; Ruggenenti P; Sunder-Plassmann G
Clin J Am Soc Nephrol; 2010 Feb; 5(2):379-85. PubMed ID: 20056752
[TBL] [Abstract][Full Text] [Related]
3. Fabry disease with aortic regurgitation.
Choi S; Seo H; Park M; Kim J; Hwang S; Kwon K; Her K; Won Y
Ann Thorac Surg; 2009 Feb; 87(2):625-8. PubMed ID: 19161799
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.
Weidemann F; Niemann M; Breunig F; Herrmann S; Beer M; Störk S; Voelker W; Ertl G; Wanner C; Strotmann J
Circulation; 2009 Feb; 119(4):524-9. PubMed ID: 19153271
[TBL] [Abstract][Full Text] [Related]
5. [Enzyme replacement therapy in Fabry's disease].
Alvarez L; del Pozo C; Trigueros M; Sánchez L; Albero MD; López-Menchero R; Ortega E
Nefrologia; 2005; 25(3):322-7. PubMed ID: 16053014
[TBL] [Abstract][Full Text] [Related]
6. Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy.
Desnick RJ; Banikazemi M
Nephrol Ther; 2006 Jan; 2 Suppl 2():S172-85. PubMed ID: 17373219
[TBL] [Abstract][Full Text] [Related]
7. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
Breunig F; Wanner C
J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
[TBL] [Abstract][Full Text] [Related]
8. [Renal involvement in Fabry's disease: diagnosis, follow-up and enzyme replacement therapy].
Mignani R; Feriozzi S; Carraro G; Martinelli F; Cianciaruso B
G Ital Nefrol; 2009; 26(5):577-84. PubMed ID: 19802803
[TBL] [Abstract][Full Text] [Related]
9. Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy.
Üçeyler N; He L; Schönfeld D; Kahn AK; Reiners K; Hilz MJ; Breunig F; Sommer C
J Peripher Nerv Syst; 2011 Dec; 16(4):304-14. PubMed ID: 22176145
[TBL] [Abstract][Full Text] [Related]
10. [Two cases of heterozygous Fabry disease].
Shibuya Y; Oku N; Suzuki Y; Gomi T
Nihon Jinzo Gakkai Shi; 2006; 48(5):421-7. PubMed ID: 16913464
[TBL] [Abstract][Full Text] [Related]
11. Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults.
Ortiz A; Oliveira JP; Wanner C; Brenner BM; Waldek S; Warnock DG
Nat Clin Pract Nephrol; 2008 Jun; 4(6):327-36. PubMed ID: 18431378
[TBL] [Abstract][Full Text] [Related]
12. Cardiac Fabry's disease: an unusual cause of left ventricular hypertrophy.
Nunes JP; Costa O; Faria Mdo S; Almeida PB; Lacerda L
Nat Clin Pract Cardiovasc Med; 2007 Nov; 4(11):630-3. PubMed ID: 17957210
[TBL] [Abstract][Full Text] [Related]
13. Fabry disease: case report with emphasis on enzyme replacement therapy and possible future therapeutic options.
Möhrenschlager M; Pontz BF; Lanzl I; Podskarbi T; Henkel V; Ring J
J Dtsch Dermatol Ges; 2007 Jul; 5(7):594-7. PubMed ID: 17610610
[TBL] [Abstract][Full Text] [Related]
14. Amelioration of white-matter lesions in a patient with Fabry disease.
Yamadera M; Yokoe M; Beck G; Mihara M; Oe H; Yamamoto Y; Sakoda S
J Neurol Sci; 2009 Apr; 279(1-2):118-20. PubMed ID: 19185318
[TBL] [Abstract][Full Text] [Related]
15. [Fabry disease: diagnostic due of substitutive enzyme-therapy].
Barbey F; Widmer U; Burnier M; Lidove O
Rev Med Suisse Romande; 2002 Sep; 122(9):449-53. PubMed ID: 12422475
[TBL] [Abstract][Full Text] [Related]
16. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
[TBL] [Abstract][Full Text] [Related]
17. Enzyme replacement therapy for Fabry disease: morphologic and histochemical changes in the urinary sediments.
Utsumi K; Mitsuhashi F; Asahi K; Sakurazawa M; Arii K; Komaba Y; Katsumata T; Katsura K; Kase R; Katayama Y
Clin Chim Acta; 2005 Oct; 360(1-2):103-7. PubMed ID: 16112661
[TBL] [Abstract][Full Text] [Related]
18. Cystatin C as a marker of early changes of renal function in Fabry nephropathy.
Feriozzi S; Germain DP; Di Vito R; Legrand A; Ricci R; Barbey F
J Nephrol; 2007; 20(4):437-43. PubMed ID: 17879210
[TBL] [Abstract][Full Text] [Related]
19. Fabry nephropathy and the case for adjunctive renal therapy.
Wanner C; Breunig F
J Am Soc Nephrol; 2007 Sep; 18(9):2426-8. PubMed ID: 17699807
[No Abstract] [Full Text] [Related]
20. Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement.
Pisani A; Spinelli L; Sabbatini M; Andreucci MV; Procaccini D; Abbaterusso C; Pasquali S; Savoldi S; Comotti C; Cianciaruso B
Am J Kidney Dis; 2005 Jul; 46(1):120-7. PubMed ID: 15983965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]